Actively Recruiting
A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection
Led by Astellas Pharma Korea, Inc. · Updated on 2026-05-14
202
Participants Needed
18
Research Sites
195 weeks
Total Duration
On this page
Sponsors
A
Astellas Pharma Korea, Inc.
Lead Sponsor
S
Seagen Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
Enfortumab vedotin (or PADCEV Injection) is a treatment for cancer in the bladder lining (urothelial cancer). PADCEV Injection is now available to treat this cancer. People in this study will be adults in South Korea with locally advanced or metastatic urothelial cancer. Metastatic means the cancer has spread to other parts of the body. During their care, the person's doctor will have prescribed PADCEV Injection and other medicines to treat their cancer. People in the study will be treated according to their clinic's standard practice. This study is about collecting information only. This study will survey people who know they are receiving PADCEV Injection. The aims of the study are to check outcomes of treatment with PADCEV and record any medical problems during the study. Once a doctor has prescribed PADCEV Injection, a person in the study will be observed for up to 48 weeks (about 1 year) after their first dose. During this time, a person's medical records will be reviewed to check for any medical problems and to follow the condition of their cancer. If a person in the study stops taking PADCEV Injection sooner than 48 weeks, records will be reviewed until 30 days (1 month) after each person's last dose of PADCEV Injection or until they start a different medicine for their cancer.
CONDITIONS
Official Title
A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients who receive treatment with PADCEV Injection, according to the approved local label.
You will not qualify if you...
- Patients with any contraindication for PADCEV Injection, according to the approved local label.
- Patients who receive or are going to receive any investigational medicine during the observation period.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 18 locations
1
Site KR82001
Goyang-si, Gyeonggi-do, South Korea, 10408
Actively Recruiting
2
Site KR82012
Suwon, Gyeonggi-do, South Korea, 16247
Actively Recruiting
3
Site KR82008
Suwon, Gyeonggi-do, South Korea, 16500
Actively Recruiting
4
Site KR82007
Jeollanam-do, Jeollanam-do, South Korea, 58128
Completed
5
Site KR82013
Jeonju, Jeonbuk-do, South Korea, 54907
Actively Recruiting
6
Site KR82015
Busan, South Korea, 47392
Active, Not Recruiting
7
Site KR82010
Busan, South Korea, 48108
Completed
8
Site KR82009
Busan, South Korea, 49201
Active, Not Recruiting
9
Site KR82016
Busan, South Korea, 50612
Completed
10
Site KR82014
Daegu, South Korea, 42415
Actively Recruiting
11
Site KR82018
Daejeon, South Korea, 35365
Actively Recruiting
12
Site KR82004
Incheon, South Korea, 21565
Active, Not Recruiting
13
Site KR82002
Seoul, South Korea, 02841
Actively Recruiting
14
Site KR82005
Seoul, South Korea, 03181
Actively Recruiting
15
Site KR82003
Seoul, South Korea, 03722
Active, Not Recruiting
16
Site KR82017
Seoul, South Korea, 06351
Active, Not Recruiting
17
Site KR82006
Seoul, South Korea, 07417
Actively Recruiting
18
Site KR82011
Seoul, South Korea, 07985
Actively Recruiting
Research Team
A
Astellas Pharma Global Development, Inc.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here